Lantheus Medical Imaging parent Lantheus Holdings and radiation therapy equipment developer RefleXion Medical have signed a development and marketing partnership to evaluate the use of Lantheus' prostate-specific membrane antigen (PSMA)-targeted PET agent piflufolastat F-18 with RefleXion's X1 biology-guided radiotherapy system.
RefleXion X1 combines PET technology with radiation therapy delivery, allowing for real-time treatment guidance using tumor biology, Lantheus said.
The agreement will be managed by a joint steering committee and will be focused on securing U.S. regulatory approval to treat patients with biology-guided radiotherapy using piflufolastat F-18.
